UK Explains New ‘Reliance’ Routes To Approval Based On EU Dossiers
Firms Urged To File Early To Secure Timely Decisions
Executive Summary
Companies seeking marketing authorizations in the UK or Great Britain will be able to make use of two new “reliance” procedures offering regulatory assessment times of 67 days or less if their products have already gone through the EU centralized or decentralized approval systems.
You may also be interested in...
Enhertu Nabs A First With UK Standalone Approval
The UK conditional approval of Daiichi Sankyo/AstraZeneca’s advanced breast cancer drug Enhertu was issued in accordance with “transitional provisions” that apply to drugs that received a positive opinion from the European Medicines Agency before the end of the Brexit transition period.
EU Ups The Ante On Opposition To COVID-19 IP Waiver
Leaked documents show that the European Commission has prepared a new proposal on compulsory licensing of coronavirus products to be tabled at the World Trade Organization’s Ministerial Conference next month.
EFPIA On Why More EU Drug Price Transparency Isn’t The Answer
As discussions continue over the European Commission’s plans to overhaul the EU pharmaceutical legislation, the R&D-based pharma industry body EFPIA says that any new pharma policy framework will need to be stable, fast, effective and globally competitive.